Immune response of mature cows subjected to annual booster vaccination against neonatal calf diarrhoea with two different commercial vaccines: A non-inferiority study

Abstract Neonatal calf diarrhoea can have important economic consequences. Scour vaccines are available against some of the most frequent pathogens responsible for this disease: Bovine Rotavirus (BoRV), Bovine Coronavirus (BoCV) and E. coli K99. In this multi-centre, randomised, blinded study, adult cows vaccinated with a trivalent vaccine marketed for years (Rotavec™ Corona, MSD Animal Health - RC) prior to last parturition were revaccinated 12–15 months later, prior to the upcoming parturition, with either a single injection of a recently marketed vaccine (Bovigen™ Scour, Virbac - BS), or RC. The aim of this trial was to verify whether BS is not inferior to RC for the stimulation of the immune response and the passive transfer to calves in these conditions. A total of 136 multiparous dairy cows, from 5 different herds and located in 3 countries (France, UK and Germany) were enrolled in the study. Sixty-five cows were vaccinated with BS and 71 with RC. Antibody levels, measured by competitive ELISA and represented as percentage of inhibition (PI), were assessed in the cow's serum (on the day of vaccination: D0 and on days 21, 42 and at calving), in the colostrum and in the serum of calves in the first week of life. Differences in means of PI between groups and the 95% confidence interval (CI) were calculated. The non-inferiority threshold was set at −10%. The relationships between antibody levels in the colostrum and the vaccination-calving interval (VCI) or the inter-booster vaccination interval (IBVI) were also analysed. All the lower margins of the 95% CI of the difference in means of PI, in all samples and for the 3 pathogens assessed, were above −10%. This result shows that BS is not inferior to RC for the stimulation of the immune response against BoRV, BoCV and E. coli K99 and the passive transfer of immunity to calves when this vaccine is administered to their dams previously vaccinated with RC. Furthermore, no correlation was found between PI values in the colostrum and the VCI or IBVI. The ratio of animals with a PI ≥ 95% in the colostrum, among cows with similar intervals, was not significantly different between groups, for all antigens tested. Therefore, this study shows that a single injection of the heterologous vaccine BS can be used as a booster in cattle previously vaccinated with RC.